NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES AND PRACTICES
Description of the Business
Astronics Corporation (“Astronics” or the “Company”) is a leading provider of advanced technologies to the global aerospace, defense, and electronics industries. Our products and services include advanced, high-performance electrical power generation, distribution and seat motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures and automated test systems.
We have principal operations in the United States (“U.S.”), Canada, France and Germany, as well as engineering offices in Ukraine and India.
The Company has two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the global aerospace and defense industry. Our Test Systems segment designs, develops, manufactures and maintains automated test systems that support the aerospace and defense, communications and mass transit industries as well as training and simulation devices for both commercial and military applications.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.
The Company accounts for its acquisitions under Accounting Standard Codification (“ASC”) Topic 805, Business Combinations and Reorganizations (“ASC Topic 805”). ASC Topic 805 provides guidance on how the acquirer recognizes and measures the consideration transferred, identifiable assets acquired, liabilities assumed, non-controlling interests, and goodwill acquired in a business combination.
See Note 21, Acquisitions, for details of our recent acquisitions.
Cost of Products Sold, Research and Development and Selling, General and Administrative Expenses
Cost of Products Sold includes the costs to manufacture products such as direct materials and labor and manufacturing overhead as well as all engineering and developmental costs. The Company is engaged in a variety of research and development activities directed to the substantial improvement or new application of the Company’s existing technologies. Research and development costs are expensed as incurred and include salaries, benefits, consulting, material costs and depreciation. Research and development costs amounted to $43.5 million in 2025. Beginning in 2025, the Company changed its financial statement presentation of research and development costs. These costs were previously included within Cost of Products Sold and were included in arriving at Gross Profit. Research and development expenses, which amounted to $52.1 million in 2024 and $53.7 million in 2023 have been reclassified from Cost of Products Sold to a separate line item below Gross Profit in the accompanying Consolidated Statements of Operations. All periods presented have been revised to reflect this presentation. Selling, General and Administrative (“SG&A”) expenses include costs primarily related to our sales, marketing and administrative departments. Interest expense is shown net of interest income. Interest income was insignificant for the years ended December 31, 2025, 2024 and 2023.
Simplification Initiatives
During 2025, the Company initiated simplification activities in the Aerospace segment, including costs related to footprint rationalization and portfolio shaping. Restructuring charges, including a reduction of inventory and impairment of other long-lived assets, were recorded as a result of these simplification initiatives. In the year ended December 31, 2025, the Company recorded $5.8 million and $0.4 million in simplification initiative charges to Cost of Products Sold and Selling, General and Administrative Expenses, respectively, in the accompanying Consolidated Statements of Operations.
Shipping and Handling
Shipping and handling costs are included in Cost of Products Sold.
Equity-Based Compensation
The Company accounts for its stock options following ASC Topic 718, Compensation – Stock Compensation (“ASC Topic 718”). ASC Topic 718 requires all equity-based payments to employees, including grants of employee stock options and RSUs, to be recognized in the statement of earnings based on the grant date fair value of the award. For awards with graded vesting,
the Company uses a straight-line method of attributing the value of stock-based compensation expense, subject to minimum levels of expense, based on vesting. The Company accounts for forfeitures as they occur.
Under ASC Topic 718, stock compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Equity-based compensation expense is included in SG&A Expenses.
Cash and Cash Equivalents
All highly liquid instruments with a maturity of three months or less at the time of purchase are considered cash equivalents.
Restricted Cash
Under the provisions of the ABL Revolving Credit Facility (as defined and discussed below in Note 8, Long-Term Debt) which was terminated on October 22, 2025, the Company had a cash dominion arrangement with the banking institution for its accounts within the United States whereby daily cash receipts were contractually utilized to pay down outstanding balances on the ABL Revolving Credit Facility. Account balances that had not yet been applied to the ABL Revolving Credit Facility were classified as restricted cash in the accompanying Consolidated Balance Sheets. The following table provides a reconciliation of cash and restricted cash included in Consolidated Balance Sheets to the amounts included in the Consolidated Statements of Cash Flows.
| | | | | | | | | | | | | | |
| | December 31, |
| (In thousands) | | 2025 | | 2024 |
| Cash and Cash Equivalents | | $ | 18,180 | | | $ | 9,285 | |
| Restricted Cash | | — | | | 9,143 | |
| Total Cash and Restricted Cash Shown in Statements of Cash Flows | | $ | 18,180 | | | $ | 18,428 | |
Customer Bankruptcies
In October 2024, a customer reported within the Aerospace segment declared bankruptcy. As a result, the Company recorded a full reserve of $1.0 million for outstanding receivables, a reserve of $1.7 million for inventory and $0.6 million for impairment of fixed assets.
In November 2023, a non-core contract manufacturing customer reported within the Aerospace segment filed for bankruptcy under Chapter 11. As a result, the Company recorded a full reserve of $7.5 million for outstanding accounts receivable and a reserve of $3.6 million for inventory.
Accounts Receivable and Allowance for Estimated Credit Losses
Accounts receivable are composed of trade and contract receivables recorded at either the invoiced amount or costs in excess of billings. These receivables are expected to be collected within one year and do not bear interest. The Company records a valuation allowance to account for estimated credit losses. The estimate for credit losses is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as the age of the receivable balances, historical experience, credit quality, current economic conditions, and reasonable and supportable forecasts of future economic conditions that may affect a customer’s ability to pay. Balances are written off when determined to be uncollectible.
Although the Company has historically not experienced significant credit losses, the Company’s exposure to credit losses may increase if its customers are adversely affected by global economic recessions, industry conditions, or other customer-specific factors.
Inventories
We record our inventories at the lower of cost or net realizable value. We determine the cost basis of our inventory on a first-in, first-out or weighted average basis using a standard cost methodology that approximates actual cost. Inventory costs include direct materials, direct labor, and manufacturing overhead, including freight-in, custom duties, and import tariffs directly attributable to bringing the inventory to its existing location and condition. The Company records reserves to provide for excess, slow moving or obsolete inventory. In determining the appropriate reserve, the Company considers the age of inventory on hand, the overall inventory levels in relation to forecasted demands as well as reserving for specifically identified inventory that the Company believes is no longer salable or whose value has diminished.
Cloud Computing Arrangements
The Company incurs costs to implement cloud computing arrangements that are hosted by third party vendors. Implementation costs associated with cloud computing arrangements are capitalized when incurred during the application development phase. Amortization is calculated on a straight-line basis over the contractual term of the cloud computing arrangement. Implementation costs associated with cloud computing arrangements are reflected in Cash from Operating Activities on the Consolidated Statements of Cash Flows in accordance with ASC Topic 350-40, Intangibles - Goodwill and Other - Internal-Use Software. The Company capitalized $2.8 million related to such arrangements within other non-current assets in the Consolidated Balance Sheets as of December 31, 2025. Costs capitalized were insignificant as of December 31, 2024. Amortization expense was insignificant in 2025, 2024 and 2023.
Property, Plant and Equipment
Property, plant and equipment (“PP&E”) are recorded at cost less accumulated depreciation. Depreciation of property, plant and equipment is computed using the straight-line method for financial reporting purposes and using accelerated methods for income tax purposes. Estimated useful lives of the assets are as follows: buildings, 25-40 years; and machinery and equipment, 4-10 years. Leased buildings and associated leasehold improvements are amortized over the shorter of the terms of the lease or the estimated useful lives of the assets, with the amortization of such assets included within depreciation expense.
The cost of properties sold or otherwise disposed of and the accumulated depreciation thereon are eliminated from the accounts and the resulting gain or loss, as well as maintenance and repair expenses, is reflected within operating income. Replacements and improvements are capitalized.
Depreciation expense was approximately $10.2 million, $11.5 million and $12.2 million in 2025, 2024 and 2023, respectively.
Deferred Financing Costs
The Company incurs debt issuance costs in connection with amending or entering into new credit facilities. These costs are amortized as an adjustment to interest expense over term of the credit facility on a straight-line basis, which approximates the effective interest method. This amortization expense is included in interest expense in the Company’s Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense, loss on debt settlement or a reduction to equity based on the nature of the debt instrument.
See Note 8, Long-Term Debt, for details of our deferred financing costs.
Long-Lived Assets
Long-lived assets to be held and used are initially recorded at cost. The carrying value of these assets is evaluated for recoverability whenever adverse effects or changes in circumstances indicate that the carrying amount may not be recoverable. Impairments are recognized if future undiscounted cash flows from operations are not expected to be sufficient to recover long-lived assets. The carrying amounts are then reduced to fair value, which is typically determined by using a discounted cash flow model.
Assets held for sale are to be reported at lower of its carrying amount or fair value less cost to sell. Judgment is required in estimating the sales price of assets held for sale and the time required to sell the assets. These estimates are based upon available market data and operating cash flows of the assets held for sale.
Goodwill
The Company tests goodwill at the reporting unit level on an annual basis or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
We may elect to perform a qualitative assessment that considers economic, industry and company-specific factors for all or selected reporting units. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative test. We may also elect to perform a quantitative test instead of a qualitative test for any or all of our reporting units.
Quantitative testing requires a comparison of the fair value of each reporting unit to its carrying value. We use the discounted cash flow method to estimate the fair value of our reporting units. The discounted cash flow method incorporates various assumptions, the most significant being projected sales growth rates, operating margins and cash flows, the terminal growth rate and the weighted average cost of capital, which are Level 3 inputs in the fair value hierarchy. If the carrying value of the
reporting unit exceeds its fair value, goodwill impairment is measured as the amount by which the reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill.
The 2025, 2024 and 2023 assessments indicated no impairment to the carrying value of goodwill in any of the Company’s reporting units and no impairment charges were recognized.
Intangible Assets
The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized, but are reviewed for impairment at least annually or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment is tested under ASC Topic 350, Intangibles - Goodwill and Other, as amended by ASU 2012-2.
The 2025, 2024 and 2023 assessments indicated no impairment to the intangible assets of the Company and no impairment charges were recognized.
Financial Instruments
The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and long-term debt. The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company does not hold or issue financial instruments for trading purposes. Due to their short-term nature, the carrying values of cash and equivalents, restricted cash, accounts receivable and accounts payable approximate fair value. The carrying value of the Company’s variable rate long-term debt instruments also approximates fair value due to the variable rate feature of these instruments. The Company estimates the fair value of the convertible notes based on quoted prices for these instruments in active markets, classified as Level 1 measurements within the fair value hierarchy. The fair value of the 2030 Convertible Notes was approximately $84.8 million and $176.9 million as of December 31, 2025 and 2024, respectively. The fair value of the 2031 Convertible Notes was approximately $264.1 million as of December 31, 2025.
From time to time, the Company makes long-term, strategic equity investments in companies to promote business and strategic objectives. These investments as classified within other assets in the Consolidated Balance Sheets. For investments requiring equity method accounting, we recognize our share of the investee’s earnings or losses within Other Expense, Net of Other Income in the Consolidated Statements of Operations. For investments not requiring equity method accounting, if the investment has no readily determinable fair value, we have elected the practicability exception of ASU 2016-01, under which the investment is measured at cost, less impairment, plus or minus observable price changes from orderly transactions of an identical or similar investment of the same issuer.
We recognized income of $1.8 million associated with the reversal of a liability related to an equity investment, as we were no longer required to make an associated payment. This amount is included in Other Expense, Net of Other Income in the Consolidated Statement of Operations in 2023.
Deferred Tax Asset Valuation Allowance
The Company records a valuation allowance against the deferred tax assets if and to the extent it is more likely than not that the Company will not recover the deferred tax assets. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, and considers among other factors, historical financial performance, projected future taxable income, scheduled reversals of deferred tax liabilities, the overall business environment, and tax planning strategies. After considering the losses in recent periods and cumulative pre-tax losses in the three-year period ending with the current year, the Company determined that projections of future taxable income could not be relied upon as a source of income to realize its deferred tax assets. However, the Company is relying on a significant portion of its existing deferred tax liabilities for the realizability of deferred tax assets. As a result, the Company has valuation allowances against its deferred tax assets of approximately $74.5 million, $78.7 million, and $65.6 million during the years ended December 31, 2025, 2024 and 2023, respectively, for the portion of deferred tax assets not realizable by the Company’s existing deferred tax liabilities.
Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities and the reported amounts of sales and expenses during the reporting periods in the financial statements and accompanying notes. Actual results could differ from those estimates.
Foreign Currency Translation
The Company accounts for its foreign currency translation in accordance with ASC Topic 830, Foreign Currency Translation. The aggregate transaction gains and losses included in operations were insignificant in 2025, 2024 and 2023.
Dividends
The Company has not paid any cash dividends in the three-year period ended December 31, 2025.
Loss Contingencies
Loss contingencies may from time to time arise from situations such as claims and other legal actions. Loss contingencies are recorded as liabilities when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. In all other instances, legal fees are expensed as incurred. Disclosure is required when there is a reasonable possibility that the ultimate loss will exceed the recorded provision. Contingent liabilities are often resolved over long time periods. In recording liabilities for probable losses, management is required to make estimates and judgments regarding the amount or range of the probable loss. Management continually assesses the adequacy of estimated loss contingencies and, if necessary, adjusts the amounts recorded as better information becomes known.
Recent Accounting Pronouncements
Recent Accounting Pronouncements Adopted
| | | | | | | | | | | | | | |
| Standard | | Description | | Financial Statement Effect or Other Significant Matters |
| ASU No. 2024-04 -Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments | | The amendments in this update clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or an extinguishment. | | We early adopted this standard during 2025 and applied it on a prospective basis. Refer to Note 8. |
ASU No. 2023-09 - Income Taxes (Topic 740), Improvements to Income Tax Disclosures | | The amendments in this update require enhanced disclosures within the annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclosure of both percentages and dollar amounts, and disaggregation of the reconciling items by nature when they meet a quantitative threshold. The update also includes enhanced disclosure requirements for income taxes paid. | | We adopted this standard beginning in 2025 and applied it on a prospective basis. Refer to Note 11. |
ASU No. 2025-06 -Intangibles, Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software | | The amendments in this update remove all references to project stages and clarify the threshold entities apply to begin capitalizing software costs. The update further specifies required disclosures for all capitalized internal-use software costs. This guidance is effective for fiscal years beginning after December 15, 2027 and interim periods within that period. Early adoption is permitted. | | We early adopted this standard for the fourth quarter of the fiscal year ending December 31, 2025 using a prospective transition approach. The effect was immaterial to our Consolidated Financial Statements. |
Recent Accounting Pronouncements Not Yet Adopted
| | | | | | | | | | | | | | |
| Standard | | Description | | Financial Statement Effect or Other Significant Matters |
ASU No. 2025-05 -Financial Instruments, Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets | | The amendments in this update provide a practical expedient that allows entities to assume current conditions as of the balance sheet date remain unchanged over the life of current accounts receivable and contract assets when developing forecasts for estimated expected credit losses. This guidance is effective for fiscal years beginning after December 15, 2025 and interim periods within that period. Early adoption is permitted. | | The Company is currently reviewing the guidance and evaluating the impact on our Consolidated Financial Statements and related disclosures. |
ASU No. 2024-03 - Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures (Topic 220), Disaggregation of Income Statement Expenses | | This standard requires disclosure of specified information about certain cost and expenses at each interim and annual reporting period. This includes disclosure of the amounts of purchases of inventory, employee compensation, depreciation and intangible asset for each relevant expense caption on the income statement, as well as the total amount of selling expenses. Additionally, the amendments require disclosing a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated. The provisions of the standard are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. | | The Company is currently reviewing the guidance and evaluating the impact on our Consolidated Financial Statements and related disclosures. |
We consider the applicability and impact of all ASUs. ASUs not listed above were assessed and determined to be either not applicable or had or are expected to have minimal impact on our financial statements and related disclosures.
NOTE 2 — REVENUE
Revenue is recognized when, or as, the Company transfers control of promised products or services to a customer in an amount that reflects the consideration the Company expects to be entitled in exchange for transferring those products or services. Sales shown on the Company’s Consolidated Statements of Operations are from contracts with customers.
Payment terms and conditions vary by contract, although terms generally include a requirement of payment within a range from 30 to 90 days after the performance obligation has been satisfied; or in certain cases, up-front deposits. In circumstances where the timing of revenue recognition differs from the timing of receipt of consideration, the Company has determined that the Company’s contracts generally do not include a significant financing component. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from sales.
The Company recognizes an asset for the incremental, material costs of obtaining a contract with a customer if the Company expects the benefit of those costs to be longer than one year and the costs are expected to be recovered. These incremental costs include, but are not limited to, sales commissions incurred to obtain a contract with a customer. The Company has elected the practical expedient available under ASC 340-40-25-4 to immediately expense the incremental cost of obtaining a contract when the expected benefit of those costs is less than one year. As of December 31, 2025 and 2024, the Company did not have material incremental costs on any open contracts with an original expected duration of greater than one year.
The Company recognizes an asset for certain, material costs to fulfill a contract if it is determined that the costs relate directly to a contract or an anticipated contract that can be specifically identified, generate or enhance resources that will be used in satisfying performance obligations in the future, and are expected to be recovered. Such costs are amortized on a systematic basis that is consistent with the transfer to the customer of the goods to which the asset relates. Start-up costs are expensed as incurred. Capitalized fulfillment costs are included in Inventories in the accompanying Consolidated Balance Sheets. Should future orders not materialize or it is determined the costs are no longer probable of recovery, the capitalized costs are written off. The Company has capitalized $6.0 million and $8.3 million of costs as of December 31, 2025 and 2024, respectively. Amortization of fulfillment costs recognized within Cost of Products Sold was $3.5 million and $3.1 million in 2025 and 2024, respectively. No amortization of fulfillment costs was recorded in 2023.
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account. The majority of our contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts which are, therefore, not distinct. Thus, the contract’s
transaction price is the revenue recognized when or as that performance obligation is satisfied. Promised goods or services that are immaterial in the context of the contract are not separately assessed as performance obligations.
In contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation based on the estimated standalone selling price of each distinct good or service in the contract. In these cases, the Company uses an expected cost plus margin approach to determine the standalone selling price for each performance obligation. Shipping and handling activities that occur after the customer has obtained control of the good are considered fulfillment activities, not performance obligations.
Contract modifications are routine in the performance of our contracts, and contracts may be modified to account for changes in contract specifications or requirements. In most instances, contract modifications are for goods or services that are distinct, and, therefore, are accounted for as new contracts. The effect of modifications has been reflected when identifying the satisfied and unsatisfied performance obligations, determining the transaction price and allocating the transaction price.
The majority of the Company’s revenue from contracts with customers is recognized at a point in time, when the customer obtains control of the promised product. In general, the customer has obtained control when they have legal title, significant risks and rewards of ownership of the asset, and the Company has a present right to payment for the product. From time to time, contracts may contain variable consideration, which could include incremental fees or penalty provisions related with performance. In these situations, variable consideration is included in the estimated transaction price based on an assessment of all information (i.e., historical, current and forecasted) that is reasonably available to the Company and updated at the end of each reporting period as additional information becomes available. Most of our contracts do not contain rights to return product; where this right does exist, it is evaluated as possible variable consideration.
For contracts that are subject to the requirement to accrue anticipated losses, the Company recognizes the entire anticipated loss in the period that the loss becomes probable.
For contracts with customers in which the Company promises to provide a product to the customer that has no alternative use to the Company and the Company has enforceable rights to payment for progress completed to date inclusive of profit, the Company satisfies the performance obligation and recognizes revenue over time, using costs incurred to date relative to total estimated costs at completion to measure progress toward satisfying our performance obligations. Incurred costs represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, material and overhead.
The Company also recognizes revenue from service contracts (including service-type warranties) over time. The Company recognizes revenue over time during the term of the agreement as the customer is simultaneously receiving and consuming the benefits provided throughout the Company’s performance. The Company typically recognizes revenue over time using a cost-to-cost method, where revenues are recognized proportionally as costs are incurred, or on a straight-line basis throughout the contract period.
On December 31, 2025, we had $674.5 million of remaining performance obligations, which we refer to as total backlog. We expect to recognize approximately $533.1 million of our remaining performance obligations as revenue in 2026.
Costs in excess of billings includes unbilled amounts resulting from revenues under contracts with customers that are satisfied over time and when the cost-to-cost measurement method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Amounts may not exceed their net realizable value. Costs in excess of billings are classified as current assets, within Accounts Receivable, Net of Allowance for Estimated Credit Losses on our Consolidated Balance Sheets.
Billings in excess of cost includes billings in excess of revenue recognized as well as other elements of deferred revenue, which includes advanced payments, up-front payments, and progress billing payments. Billings in excess of cost are reported in our Consolidated Balance Sheets classified as current liabilities, within Customer Advance Payments and Deferred Revenue, and non-current liabilities, within Other Liabilities.
The Company’s contract assets and contract liabilities consist primarily of costs and profits in excess of billings and billings in excess of cost and profits, respectively. The following table presents the beginning and ending balances of contract assets and contract liabilities:
| | | | | | | | | | | |
| (In thousands) | Contract Assets | | Contract Liabilities |
Beginning Balance, January 1, 2025 | $ | 54,171 | | | $ | 28,171 | |
Ending Balance, December 31, 2025 | $ | 54,687 | | | $ | 26,962 | |
The increase in contract assets reflects the net impact of new revenue recognized in excess of billings exceeding billing of previously unbilled revenue during the period, partially offset by $8.3 million in revisions of estimated costs to complete certain long-term mass transit Test contracts which were recorded in 2025. The revisions resulted in reduced revenue recognized during 2025 due to lower estimates of the percentage of work completed on the programs. The decrease in contract liabilities reflects the net impact of revenue recognized in excess of new customer advances or deferred revenues recorded.
We recognized $20.8 million and $16.8 million during the year ended December 31, 2025 and 2024, respectively, in revenues that were included in the contract liability balance at the beginning of the period.
The following table presents our revenue disaggregated by Market Segments as of December 31 as follows: | | | | | | | | | | | | | | | | | | | | |
| (In thousands) | | 2025 | | 2024 | | 2023 |
| Aerospace Segment | | | | | | |
Commercial Transport | | $ | 599,301 | | | $ | 524,572 | | | $ | 432,199 | |
Military Aircraft | | 116,276 | | | 88,019 | | | 61,617 | |
General Aviation | | 69,834 | | | 74,344 | | | 80,842 | |
Other | | 11,908 | | | 19,749 | | | 30,172 | |
| Aerospace Total | | 797,319 | | | 706,684 | | | 604,830 | |
| | | | | | |
| Test Systems Segment | | | | | | |
| | | | | | |
Government & Defense | | 64,809 | | | 88,742 | | | 84,376 | |
| Test Systems Total | | 64,809 | | | 88,742 | | | 84,376 | |
| | | | | | |
| Total | | $ | 862,128 | | | $ | 795,426 | | | $ | 689,206 | |
The following table presents our revenue disaggregated by Product Lines as of December 31 as follows: | | | | | | | | | | | | | | | | | | | | |
| (In thousands) | | 2025 | | 2024 | | 2023 |
| Aerospace Segment | | | | | | |
Electrical Power & Motion | | $ | 410,382 | | | $ | 359,043 | | | $ | 268,049 | |
Lighting & Safety | | 208,897 | | | 179,403 | | | 157,434 | |
Avionics | | 123,422 | | | 120,183 | | | 113,117 | |
Systems Certification | | 29,069 | | | 17,003 | | | 26,255 | |
Structures | | 13,641 | | | 11,303 | | | 9,803 | |
Other | | 11,908 | | | 19,749 | | | 30,172 | |
| Aerospace Total | | 797,319 | | | 706,684 | | | 604,830 | |
| | | | | | |
| Test Systems | | 64,809 | | | 88,742 | | | 84,376 | |
| | | | | | |
| Total | | $ | 862,128 | | | $ | 795,426 | | | $ | 689,206 | |
| | | | | | |
NOTE 3 — ACCOUNTS RECEIVABLE
Accounts receivable at December 31 consists of: | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Trade Accounts Receivable | $ | 150,832 | | | $ | 139,652 | |
| Unbilled Recoverable Costs and Accrued Profits | 54,687 | | | 54,171 | |
| Total Receivables, Gross | 205,519 | | | 193,823 | |
| Less Allowance for Estimated Credit Losses | (847) | | | (2,377) | |
| Total Receivables, Net | $ | 204,672 | | | $ | 191,446 | |
The following table provides a roll-forward of the allowance for estimated credit losses that is deducted from accounts receivable to present the net amount expected to be collected at December 31:
| | | | | |
| (In thousands) | |
Balance at December 31, 2023 | $ | 9,193 | |
| Bad Debt Expense, Net of Recoveries | 1,348 | |
| Write-off Charges Against the Allowance and Other Adjustments | (8,164) | |
Balance at December 31, 2024 | 2,377 | |
| Bad Debt Expense, Net of (Recoveries) | (36) | |
| Write-off Charges Against the Allowance and Other Adjustments | (1,494) | |
Balance at December 31, 2025 | $ | 847 | |
As further described in Note 1, Summary of Significant Accounting Principles and Practices, the Company recorded a $1.0 million and $7.5 million reserve for outstanding receivables for customer bankruptcies within the Aerospace segment in 2024 and 2023, respectively. The write-offs in the periods ended December 31, 2025 and 2024 relate primarily to accounts receivable reserved for in previous periods related to these customer bankruptcies.
NOTE 4 — INVENTORIES
Inventories at December 31 are as follows: | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Finished Goods | $ | 32,838 | | | $ | 27,941 | |
| Work in Progress | 38,686 | | | 31,927 | |
| Raw Material | 125,336 | | | 139,873 | |
| Total Inventories | $ | 196,860 | | | $ | 199,741 | |
At December 31, 2025, the Company’s reserve for inventory valuation was $48.7 million, or 19.8% of gross inventory. At December 31, 2024, the Company’s reserve for inventory valuation was $43.3 million, or 17.8% of gross inventory.
As further described in Note 1, Summary of Significant Accounting Principles and Practices, the Company recorded a $5.8 million reduction in inventory in the year ended December 31, 2025 in connection with simplification initiatives.
NOTE 5 — PROPERTY, PLANT AND EQUIPMENT
Property, Plant and Equipment at December 31 are as follows: | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Land | $ | 8,902 | | | $ | 8,551 | |
| Building and Improvements | 83,482 | | | 72,150 | |
| Machinery and Equipment | 131,610 | | | 125,874 | |
| Construction in Progress | 19,616 | | | 3,997 | |
| Total Property, Plant and Equipment, Gross | 243,610 | | | 210,572 | |
| Less Accumulated Depreciation | 136,532 | | | 129,885 | |
| Total Property, Plant and Equipment, Net | $ | 107,078 | | | $ | 80,687 | |
NOTE 6 — INTANGIBLE ASSETS
The following table summarizes acquired intangible assets at December 31 as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | 2025 | | 2024 |
| (In thousands) | Weighted Average Life | | Gross Carrying Amount | | Accumulated Amortization | | Gross Carrying Amount | | Accumulated Amortization |
| Patents | 11 years | | $ | 2,146 | | | $ | 2,146 | | | $ | 2,146 | | | $ | 2,146 | |
| Non-compete Agreement | 4 years | | 11,082 | | | 11,082 | | | 11,082 | | | 11,082 | |
| Trade Names | 10 years | | 11,565 | | | 10,541 | | | 11,380 | | | 10,351 | |
| Completed and Unpatented Technology | 9 years | | 47,980 | | | 45,207 | | | 47,818 | | | 42,617 | |
| Backlog | 4 years | | 3,991 | | | 177 | | | — | | | — | |
| Customer Relationships | 15 years | | 145,773 | | | 104,531 | | | 142,065 | | | 95,818 | |
| Licensing Agreement | 13 years | | 6,760 | | | 260 | | | — | | | — | |
| Total Intangible Assets | 13 years | | $ | 229,297 | | | $ | 173,944 | | | $ | 214,491 | | | $ | 162,014 | |
Amortization is computed on the straight line method for financial reporting purposes. Amortization expense for intangibles was $11.5 million, $12.9 million and $13.9 million for 2025, 2024 and 2023, respectively.
Based upon acquired intangible assets at December 31, 2025, amortization expense for each of the next five years is estimated to be:
| | | | | |
| (In thousands) | |
| 2026 | $ | 11,206 | |
| 2027 | $ | 9,498 | |
| 2028 | $ | 8,711 | |
| 2029 | $ | 7,161 | |
| 2030 | $ | 4,406 | |
NOTE 7 — GOODWILL
The following table summarizes the changes in the carrying amount of goodwill at December 31 as follows: | | | | | | | | | | | | | | | | | |
| (In thousands) | Aerospace | | Test Systems | | Total |
Balance at December 31, 2023 | $ | 36,575 | | | $ | 21,635 | | | $ | 58,210 | |
| | | | | |
| | | | | |
| Foreign Currency Translations and Other | (154) | | | — | | | (154) | |
Balance at December 31, 2024 | 36,421 | | | 21,635 | | | 58,056 | |
| Acquisitions | 4,759 | | | — | | | 4,759 | |
| | | | | |
| Foreign Currency Translations and Other | 108 | | | — | | | 108 | |
Balance at December 31, 2025 | $ | 41,288 | | | $ | 21,635 | | | $ | 62,923 | |
| | | | | |
| Goodwill, Gross | $ | 161,989 | | | $ | 21,635 | | | $ | 183,624 | |
| Accumulated Impairment Losses | (120,701) | | | — | | | (120,701) | |
| Goodwill, Net | $ | 41,288 | | | $ | 21,635 | | | $ | 62,923 | |
The Company’s five reporting units with goodwill as of the first day of our fourth quarters of 2025, 2024 and 2023 were subject to the annual goodwill impairment test. Based on our assessments of our reporting units performed during our annual goodwill impairment tests, the Company concluded that no impairment to the carrying value of goodwill in any of the Company’s reporting units was indicated and no impairment charges were recognized in 2025, 2024 and 2023.
NOTE 8 — LONG-TERM DEBT
The Company entered into a $90.0 million term loan facility on January 19, 2023, and paid interest at a rate equal to SOFR (which was required to be at least 2.50%) plus 8.75%. The Company refinanced its credit facilities on July 11, 2024, and repaid in full all outstanding indebtedness under the previous term loan dated January 19, 2023.
The Company amended its asset-based revolving credit facility (the “ABL Revolving Credit Facility”) on July 11, 2024, by entering into the Seventh Amended and Restated Credit Agreement, which set the maximum aggregate amount that the Company can borrow pursuant to the revolving credit line at $200.0 million, with amounts borrowed thereunder carrying an interest rate of SOFR plus between 2.50% to 3.00%. Borrowings were subject to a borrowing base determined primarily by inventory, accounts receivable, machinery and equipment and real estate. The Company also entered into a $55.0 million term loan facility (“Term Loan Facility”) on July 11, 2024 at an interest rate of SOFR plus between 5.50% to 6.75%.
On November 25, 2024, the Company entered into a second amendment to the ABL Revolving Credit Facility which increased the maximum aggregate amount that the Company could borrow pursuant to the ABL Revolving Credit Facility to $220.0 million from $200.0 million. The maturity date of borrowings under the ABL Revolving Credit Facility was July 11, 2027. The Company and the applicable lenders also agreed in a separate first amendment to increase the amount of unsecured indebtedness the Company was permitted to incur under the ABL Revolving Credit Facility, subject to completion of the 2030 Convertible Notes offering (discussed below).
Under the terms of the ABL Revolving Credit Facility, the Company paid interest on the unpaid principal amount of the ABL Revolving Credit Facility at a rate equal to SOFR plus a term SOFR adjustment in the amount of 0.10% per annum (which collectively shall be at least 1.00%) plus an applicable margin ranging from 2.75% to 3.25% determined based upon the Company’s Excess Availability (as defined in the ABL Revolving Credit Facility). The Company was required to pay a quarterly commitment fee under the ABL Revolving Credit Facility on undrawn revolving credit commitments in an amount equal to 0.25% or 0.375% based on the Company’s average excess availability under the ABL Revolving Credit Facility.
Pursuant to the ABL Revolving Credit Facility, the Company was subject to a minimum fixed charge coverage ratio of 1.10 to 1.00. The Company was also required to maintain a minimum excess availability of the greater of 10% of the borrowing base under the ABL Revolving Credit Facility, or $15.0 million. On December 31, 2024, there was $10.0 million outstanding on the ABL Revolving Credit Facility and there remained $209.7 million available for future borrowings, net of outstanding letters of credit, before our minimum excess availability requirement.
On December 3, 2024, the Company repaid in full all outstanding indebtedness under the Term Loan Facility. The Term Loan Facility payoff consisted of a repayment of a principal amount of approximately $54.9 million, plus accrued but unpaid interest, fees and expenses, including a call premium of 3.00% which satisfied all of the Company’s indebtedness obligations thereunder. The Company funded the repayment of its obligations under the Term Loan Facility with a portion of the proceeds received from the issuance and sale of the 2030 Convertible Notes (discussed below).
On October 22, 2025, the Company entered into a $300.0 million senior secured, cash flow-based revolving credit facility (the “Revolving Credit Facility”). The Revolving Credit Facility replaced the Company’s ABL Revolving Credit Facility, which was terminated on October 22, 2025. The scheduled maturity date for the Revolving Credit Facility is October 16, 2030. Under the terms of the Revolving Credit Facility, the Company pays interest on the unpaid principal amount outstanding under the Revolving Credit Facility at a rate equal to Term SOFR (as defined in the Revolving Credit Facility) plus an applicable margin ranging from 1.25% to 2.125% determined based upon the Company’s Total Net Debt Leverage Ratio (as defined in the Revolving Credit Facility). The Company pays a quarterly commitment fee under the Revolving Credit Facility on unused Revolving Commitments ranging from 0.20% to 0.35% determined based upon the Company’s Total Net Debt Leverage Ratio.
Pursuant to the Revolving Credit Facility, the Company is subject to a total leverage ratio covenant that requires that the Company’s Total Net Debt Leverage Ratio may not exceed 4.50 to 1.00, provided that the Company’s Total Net Debt Leverage Ratio for the fiscal quarter ending December 31, 2025, may not exceed 4.75 to 1.00. The Company is also subject to a consolidated interest coverage ratio covenant that requires that the Company’s Consolidated Interest Coverage Ratio (as defined in the Revolving Credit Facility) may not be less than 3.50 to 1.00 and a secured net debt leverage ratio covenant that requires that the Company’s Secured Net Debt Leverage Ratio (as defined in the Revolving Credit Facility) may not exceed 3.00 to 1.00. As of December 31, 2025, the Company was in compliance with these covenants. On December 31, 2025, there was $85.0 million outstanding on the Revolving Credit Facility and there remained $212.8 million available for future borrowings, net of outstanding letters of credit. The Revolving Credit Facility has an accordion feature, which allows the Company to request incremental commitments of up to $100.0 million plus additional incremental amounts so long as maximum leverage requirements are met.
2030 Convertible Notes
On December 3, 2024, the Company issued $165.0 million aggregate principal amount of 5.500% Convertible Senior Notes due 2030 (the “2030 Convertible Notes”). The 2030 Convertible Notes bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2025. The 2030 Convertible Notes will mature on March 15, 2030, unless earlier converted, redeemed or repurchased. The initial conversion rate is 43.6814 shares of common stock per $1,000 principal amount of 2030 Convertible Notes, which represent the initial conversion price of $22.89
per share. The 2030 Convertible Notes are convertible at the option of the holders at any time on or after December 15, 2029, until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, the Company will satisfy its conversion obligations by paying and/or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. Beginning March 20, 2028, if the Company’s stock price has been at least 130% of the conversion price for a specified period of time, the 2030 Convertible Notes may be called at the option of the issuer. Under the same conditions, the Company can elect to redeem the 2030 Convertible Notes for cash. After the first quarter of 2025, if the Company’s stock price has been at least 130% of the conversion price for 20 of 30 trading days ending on and including the last trading day of the immediately preceding quarter, the 2030 Convertible Notes may be called at the option of the holder. During the fiscal quarter ended December 31, 2025, our stock price met the price trigger defined above, and therefore, holders of our 2030 Convertible Notes have the ability to convert their notes at their option at any time during the fiscal quarter ended April 4, 2026.
2031 Convertible Notes
On September 15, 2025, the Company issued $225.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “2031 Convertible Notes”) for net proceeds of $216.7 million. The Company used part of the net proceeds to repurchase a portion of the 2030 Convertible Notes and the remainder to enter into the capped call transactions, as further described below. The 2031 Convertible Notes do not bear any interest and will mature on January 15, 2031, unless earlier converted, redeemed or repurchased. The initial conversion rate is 18.2243 shares of common stock per $1,000 principal amount of 2031 Convertible Notes, which represents the initial conversion price of $54.87 per share. The 2031 Convertible Notes are convertible at the option of the holders at any time on or after October 15, 2030, until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, the Company will satisfy its conversion obligations by paying cash up to the aggregate principal amount of the 2031 Convertible Notes to be converted and paying and/or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. Beginning January 22, 2029, if the Company’s stock price has been at least 130% of the conversion price for a specified period of time, the 2031 Convertible Notes may be called at the option of the issuer. After the fourth quarter of 2025, if the Company’s stock price has been at least 130% of the conversion price for 5 of the first 20 trading days of such fiscal quarter, the 2031 Convertible Notes may be redeemed at the option of the holder during the 30-trading day period beginning on, and including, the 21st trading day of such quarter. As of December 31, 2025, the 2031 Convertible Notes were not redeemable.
Partial Repurchase of 2030 Convertible Notes
The Company used approximately $189.8 million of the net proceeds from the issuance of the 2031 Convertible Notes, together with approximately $85.0 million of borrowings under its ABL Revolving Credit Facility and approximately $11.0 million of cash on hand, to repurchase approximately $132.0 million in aggregate principal amount of outstanding 2030 Convertible Notes pursuant to privately negotiated exchange agreements entered into with certain holders of the 2030 Convertible Notes. The total cash paid in connection with this repurchase was approximately $285.8 million. The repurchase was accounted for in accordance with ASU 2024-04, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and resulted in the recognition of an inducement charge of $32.6 million within Loss on Settlement of Debt in the Consolidated Statements of Operations. The Company also recorded a reduction to equity of $125.5 million, inclusive of a reduction to unamortized debt issuance costs of $4.3 million.
Interest expense was $12.6 million, $22.0 million and $23.3 million for 2025, 2024 and 2023, respectively.
The Company recorded non-cash write-offs of deferred financing costs related to exiting ABL lenders of approximately $0.6 million and $0.5 million in years ending December 31, 2025 and 2024, respectively, in Interest Expense within the Consolidated Statements of Operations. In 2024, the Company recorded a Loss on Settlement of Debt of approximately $10.1 million, which was comprised of $4.5 million of prepayment fees on the previous term loans and a write-off of $5.6 million of unamortized deferred financing costs.
Debt issuance cost amortization expense was $2.5 million, $2.6 million and $3.0 million for 2025, 2024 and 2023, respectively. All costs are amortized to interest expense over the term of the respective agreement. Unamortized deferred debt issuance costs associated with the Revolving Credit Facility ($3.0 million as of December 31, 2025) and ABL Revolving Credit Facility ($3.0 million as of December 31, 2024) were recorded within Other Assets.
The following table presents the outstanding principal amount and carrying value of the Convertible Notes as of the dates indicated:
| | | | | | | | | | | | | | | | | | | | | | | |
| December 31, 2025 | | December 31, 2024 |
| (In thousands) | Principal | Unamortized Debt Issuance Costs | Carrying Value | | Principal | Unamortized Debt Issuance Costs | Carrying Value |
2030 Convertible Notes | $ | 33,000 | | $ | (1,023) | | $ | 31,977 | | | $ | 165,000 | | $ | (6,331) | | $ | 158,669 | |
2031 Convertible Notes | 225,000 | | (7,526) | | 217,474 | | | — | | — | | — | |
Total | $ | 258,000 | | $ | (8,549) | | $ | 249,451 | | | $ | 165,000 | | $ | (6,331) | | $ | 158,669 | |
The Company estimates the fair value of the convertible notes based on quoted prices for these instruments in active markets, classified as Level 1 measurements within the fair value hierarchy. The fair value of the 2031 Convertible Notes was approximately $264.1 million as of December 31, 2025. The fair value of the 2030 Convertible Notes was approximately $84.8 million and $176.9 million as of December 31, 2025 and December 31, 2024, respectively.
Capped Call Transactions
In connection with the issuance of the 2031 Convertible Notes, the Company entered into capped call transactions (the “Capped Calls”) with certain financial institutions. The Capped Calls are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of the 2031 Convertible Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2031 Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the Capped Calls is initially approximately $83.41 per share of the Company’s common stock and is subject to certain adjustments under the terms of the capped call transactions. The Capped Calls expire January 15, 2031.
We used approximately $26.9 million of the net proceeds from the 2031 Convertible Notes to purchase the Capped Calls. These instruments are classified as equity and recorded as a reduction of additional paid-in capital in the Consolidated Statements of Changes in Stockholders’ Equity.
NOTE 9 — WARRANTY
In the ordinary course of business, the Company warrants its products against defects in design, materials and workmanship typically over periods ranging from twelve to sixty months. The Company determines warranty reserves needed by product line based on experience and current facts and circumstances. Activity in the warranty accrual, which is included in Other Accrued Expenses on the Consolidated Balance Sheets, is summarized as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Balance at Beginning of the Year | $ | 18,081 | | | $ | 9,751 | | | $ | 8,009 | |
| Warranty Liabilities Acquired | 995 | | | — | | | — | |
| Warranties Issued | 5,404 | | | 12,078 | | | 6,260 | |
| Reassessed Warranty Exposure | 2,066 | | | 11 | | | (397) | |
| Warranties Settled | (5,806) | | | (3,759) | | | (4,121) | |
| Balance at End of the Year | $ | 20,740 | | | $ | 18,081 | | | $ | 9,751 | |
Warranties issued includes an atypical warranty reserve for a new product launch that requires field modification that resulted in $1.4 million and $5.2 million in expense during 2025 and 2024, respectively.
NOTE 10 — LEASES
The Company has operating and finance leases for leased office and manufacturing facilities and equipment leases. We have concluded that when an agreement grants us the right to substantially all of the economic benefits associated with an identified asset, and we are able to direct the use of that asset throughout the term of the agreement, we have a lease. We lease certain office equipment under finance leases, and we lease certain production facilities, office equipment and vehicles under operating leases. Some of our leases include options to extend or terminate the leases and these options have been included in the relevant lease term to the extent that they are reasonably certain to be exercised. The right-of-use (“ROU”) assets, ROU lease liabilities, and lease costs related to the Company’s finance leases were immaterial as of December 31, 2025 and December 31, 2024.
If the lease arrangement also contains non-lease components, the Company elected the practical expedient not to separate any combined lease and non-lease components for all lease contracts. For our real estate leases, the payments used in the calculation of a new lease liability include fixed payments and variable payments (if the variable payments are based on an index) over the remaining lease term. Variable lease payments based on indices have been included in the related right-of-use assets and lease liabilities on our Consolidated Balance Sheets, while variable lease payments based on usage of the underlying asset have been excluded and are expensed in the period they are incurred, as they do not represent present rights or obligations. Variable lease components for leases relate primarily to common area maintenance charges and other separately billed lessor services, sales and real estate taxes.
Any new additional operating and financing lease liabilities and corresponding ROU assets are based on the present value of the remaining minimum rental payments. The Company’s operating lease liability increased approximately $15.3 million as a result of acquiring ROU assets from new leases entered into during the year ended December 31, 2025. In determining the incremental borrowing rate, we have considered borrowing data for secured debt obtained from our lending institution.
The following is a summary of the Company’s operating ROU assets and lease liabilities at December 31: | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | |
| Operating Leases: | | | | | |
| | | | | |
| | | | | |
| | | | | |
| Operating Right-of-Use Assets, Net | $ | 32,269 | | | $ | 23,609 | | | |
| | | | | |
| Short-term Operating Lease Liabilities | $ | 5,802 | | | $ | 4,697 | | | |
| Long-term Operating Lease Liabilities | 38,101 | | | 20,508 | | | |
| Operating Lease Liabilities | $ | 43,903 | | | $ | 25,205 | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
The following is a summary of the Company’s operating lease costs as of December 31: | | | | | | | | | | | | | | |
| (In thousands) | | 2025 | | 2024 |
| | | | |
| | | | |
| | | | |
| | | | |
| Operating Lease Cost | | 9,029 | | | 6,731 | |
| | | | |
| Variable Lease Cost | | 3,447 | | | 2,550 | |
| Short-term Lease Cost (excluding month-to-month) | | 137 | | | 178 | |
| Less Sublease and Rental Income | | (1,152) | | | (969) | |
| Total Operating Lease Cost | | $ | 11,461 | | | $ | 8,490 | |
| | | | |
The following is cash (received) paid for amounts included in the measurement of operating lease liabilities as of December 31: | | | | | | | | | | | | | | | | |
| (In thousands) | | 2025 | | 2024 | | |
| | | | | | |
| Operating Cash Flow for Operating Leases | | $ | (966) | | | $ | 6,664 | | | |
| | | | | | |
During the year ended December 31, 2025, the Company had positive operating cash flow for operating leases due to the receipt of $8.1 million tenant improvement allowances. As permitted by ASC 842, leases with expected durations of less than 12 months from inception (i.e. short-term leases) were excluded from the Company’s calculation of its lease liability and ROU asset.
The weighted-average remaining term for the Company’s operating leases is approximately 7 years. The weighted-average discount rate for the Company’s operating leases is approximately 6.4%.
The following is a summary of the Company’s maturity of operating lease liabilities: | | | | | | | | | | |
| (In thousands) | | Operating Leases | | |
| 2026 | | $ | 8,371 | | | |
| 2027 | | 7,842 | | | |
| 2028 | | 7,770 | | | |
| 2029 | | 6,931 | | | |
| 2030 | | 6,083 | | | |
| Thereafter | | 17,974 | | | |
| Total Lease Payments | | 54,971 | | | |
| Less: Interest | | 11,068 | | | |
| Total Lease Liability | | $ | 43,903 | | | |
NOTE 11 — INCOME TAXES
The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance for the amount of tax benefits which are not more likely than not to be realized.
The components of income (loss) before provision for (benefit from) income taxes are as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| United States | $ | 22,956 | | | $ | (17,426) | | | $ | (32,809) | |
| Foreign | 8,989 | | | 9,559 | | | 6,498 | |
| Income (Loss) Before Provision for (Benefit from) Income Taxes | $ | 31,945 | | | $ | (7,867) | | | $ | (26,311) | |
The provision for (benefit from) income taxes at December 31 consists of the following:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Current | | | | | |
| U.S. Federal | $ | 1,190 | | | $ | 6,026 | | | $ | (2,573) | |
| State | 1,398 | | | 985 | | | 937 | |
| Foreign | 1,360 | | | 1,357 | | | 1,600 | |
| Current | 3,948 | | | 8,368 | | | (36) | |
| | | | | |
| Deferred | | | | | |
| U.S. Federal | (449) | | | (14) | | | (336) | |
| State | (502) | | | (98) | | | 583 | |
| Foreign | (411) | | | 92 | | | (101) | |
| Deferred | (1,362) | | | (20) | | | 146 | |
| Total | $ | 2,586 | | | $ | 8,348 | | | $ | 110 | |
The following table summarizes the Company’s income tax payments net of tax refunds by jurisdiction:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| U.S. Federal | $ | 8,903 | | | | | |
| U.S. State and Local | 742 | | | | | |
| Foreign: | | | | | |
| Canada | 2,177 | | | | | |
Other1 | (217) | | | | | |
| Foreign | 1,960 | | | | | |
| Total Cash Paid for Income Taxes, Net of Refunds | $ | 11,605 | | | | | |
| Total Cash Paid for Income Taxes, Net of Refunds (Prior to ASU 2023-09) | | | $ | 3,537 | | | $ | 1,964 | |
| | | | | |
1 Includes jurisdictions below the threshold for the period presented | | | | | |
The company adopted ASU 2023-09 prospectively in 2025. The 2025 reconciliation between U.S. Federal tax rate and the effective tax rate under ASU 2023-09 is below. The reconciliation for 2024 and 2023 under the prior guidance follows.
The effective tax rates differ from the statutory federal income tax rate as follows: | | | | | | | | | | | |
| Amount (in thousands) | | Percent |
| Statutory Federal Income Tax Rate | $ | 6,708 | | | 21.0 | % |
State and Local Income Taxes, Net of Federal Income Tax Effect1 | 707 | | | 2.2 | % |
| Foreign Tax Effects | | | |
| France | | | |
| Change in Valuation Allowance | (1,243) | | | (3.9) | % |
| Other | 37 | | | 0.1 | % |
| Other Foreign Jurisdictions | 267 | | | 0.8 | % |
| Effect of Cross-Border Tax Laws | | | |
| Global Intangible Low-taxed Income | 2,307 | | | 7.2 | % |
| Foreign-derived Intangible Income | (513) | | | (1.6) | % |
| Tax Credits | | | |
| Research and Development Tax Credits | (4,291) | | | (13.4) | % |
| Change in Valuation Allowance | (8,711) | | | (27.2) | % |
| Nontaxable or Nondeductible Items | | | |
| Stock Compensation Expense | (822) | | | (2.6) | % |
| Nondeductible Premium on Bond Repurchase | 4,491 | | | 14.1 | % |
| | | |
162(m) Limitation2 | 2,675 | | | 8.4 | % |
| Other | 539 | | | 1.7 | % |
| | | |
| | | |
| IRS Audit Adjustments | 361 | | | 1.1 | % |
| Other | 74 | | | 0.2 | % |
| Effective Tax Rate | $ | 2,586 | | | 8.1 | % |
| | | |
1 State taxes in California for 2025 make up the majority (greater than 50%) of the tax effect in this category 2 Approximately $0.7 million of the line item relates to current year 162(m) limitations and the remaining amount relates to anticipated limitations of the existing deferred tax asset upon reversal |
The table below includes a reconciliation of the U.S. federal statutory rate of 21% to the Company's effective tax rate for the years ended December 31, 2024 and 2023, prior the adoption of ASU 2023-09: | | | | | | | | | | | |
| 2024 | | 2023 |
| Statutory Federal Income Tax Rate | 21.0 | % | | 21.0 | % |
| Permanent Items | | | |
| Stock Compensation Expense | (2.0) | % | | (1.4) | % |
| Meals and Entertainment | (1.7) | % | | — | % |
| Parking Expenses | (1.4) | % | | — | % |
| Other | (7.4) | % | | (1.4) | % |
| Foreign Tax Rate Differential | 7.1 | % | | (0.4) | % |
| State Income Tax, Net of Federal Income Tax Effect | (8.9) | % | | (4.6) | % |
| Research and Development Tax Credits | 47.4 | % | | 14.1 | % |
| Change in Valuation Allowance | (172.7) | % | | (26.1) | % |
| Net GILTI and FDII Tax Expense (Benefit) | 16.4 | % | | (1.0) | % |
| Penalties | (3.1) | % | | — | % |
| Other | (0.8) | % | | (0.6) | % |
| Effective Tax Rate | (106.1) | % | | (0.4) | % |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as tax attributes.
Significant components of the Company’s deferred tax assets and liabilities at December 31, are as follows: | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Deferred Tax Assets: | | | |
| Asset Reserves | $ | 22,450 | | | $ | 22,293 | |
| Deferred Compensation | 5,835 | | | 6,096 | |
| Financing Costs | 5,699 | | | — | |
| Section 163(j) - Interest Expense Limitation | 43 | | | 2,982 | |
| State Investment and Research and Development Tax Credit Carryforwards, Net of Federal Tax | 4,684 | | | 1,093 | |
| Customer Advanced Payments and Deferred Revenue | 697 | | | 257 | |
| Net Operating Loss Carryforwards and Other | 18,139 | | | 10,060 | |
| Goodwill and Intangible Assets | 575 | | | 890 | |
| ASC 606 Revenue Recognition | 428 | | | 374 | |
| Research & Development Costs | 18,754 | | | 35,061 | |
| Lease Liabilities | 10,753 | | | 6,059 | |
| Other | 4,455 | | | 6,941 | |
| Total Gross Deferred Tax Assets | 92,512 | | | 92,106 | |
| Valuation Allowance | (74,451) | | | (78,659) | |
| Deferred Tax Assets | 18,061 | | | 13,447 | |
| Deferred Tax Liabilities: | | | |
| Depreciation | 8,559 | | | 7,771 | |
| ASC 606 Revenue Recognition - Section 481(a) Adjustment | — | | | 113 | |
| Lease Assets | 8,024 | | | 5,695 | |
| Earnout Income Accrual | 104 | | | 102 | |
| Other | 1,392 | | | 1,041 | |
| Deferred Tax Liabilities | 18,079 | | | 14,722 | |
| Net Deferred Tax Liabilities | $ | (18) | | | $ | (1,275) | |
The net deferred tax assets and liabilities presented in the Consolidated Balance Sheets are as follows at December 31:
| | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Other Assets — Long-term | $ | 622 | | | $ | 159 | |
| | | |
| Deferred Tax Liabilities — Long-term | (640) | | | (1,434) | |
| | | |
| Net Deferred Tax Liabilities | $ | (18) | | | $ | (1,275) | |
The Company records a valuation allowance against the deferred tax assets if and to the extent it is more likely than not that the Company will not recover the deferred tax assets. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, and considers among other factors, historical financial performance, projected future taxable income, scheduled reversals of deferred tax liabilities, the overall business environment, and tax planning strategies. After considering the losses in recent periods and cumulative pre-tax losses in the three-year period ending with the current year, the Company determined that projections of future taxable income could not be relied upon as a source of income to realize its deferred tax assets. However, the Company is relying on a significant portion of its existing deferred tax liabilities for the realizability of deferred tax assets. As a result, the Company has valuation allowances against its deferred tax assets of approximately $74.5 million, $78.7 million, and $65.6 million during the years ended December 31, 2025, 2024 and 2023, respectively, for the portion of deferred tax assets not realizable by the Company’s existing deferred tax liabilities.
During the year ended December 31, 2025, the company recorded a deferred tax asset of approximately $6.3 million as an increase to additional paid-in capital with an offsetting valuation allowance of approximately $6.3 million as a decrease to additional paid-in capital. Any subsequently recognized tax benefits associated with this $6.3 million valuation allowance are expected to be credited directly to contributed capital.
During the year ended December 31, 2025, the Company reversed approximately $1.4 million of valuation allowances against certain foreign deferred tax assets as a result of no longer having cumulative pre-tax losses in the respective foreign jurisdictions during the three-year period ending with the current year.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law in the United States. The OBBBA permanently extends and modifies significant provisions enacted in 2017 as part of the Tax Cuts and Jobs Act (“TCJA”) that were originally set to expire at the end of 2025. In addition, the OBBBA makes changes to certain U.S. corporate tax provisions, many of which are not in effect until 2026. Key provisions of the Tax Act relevant to the Company’s operations include immediate expensing of certain domestic research and development expenses and domestic capital expenditures beginning in 2025 as well as changes to various U.S. international tax provisions going forward. The Company anticipates it will elect to deduct the remaining previously capitalized domestic research and development costs equally between 2025 and 2026 and expense domestic research and development costs as incurred for the 2025 tax year. As a result of this provision of the OBBBA, deferred tax assets related to capitalized research expenses decreased by approximately $16.3 million during the year ended December 31, 2025. The Company maintains a full valuation allowance against this deferred tax asset.
At December 31, 2025, gross federal net operating losses amounted to approximately $41.8 million, of which, $1.1 million are subject to annual limitations under Internal Revenue Code Section 382. Of these net operating losses, $0.7 million expire in 2038 and the remaining $0.4 million will carryforward indefinitely. The remaining $40.7 million of federal net operating losses, which are not subject to Internal Revenue Code Section 382 will carryforward indefinitely. The Company maintains a full valuation allowance against this deferred tax asset.
At December 31, 2025, gross state net operating loss carryforwards amounted to approximately $146.5 million. Of these state net operating loss carryforwards, $127.3 million begin to expire at various dates from 2025 through 2045 and the remaining $19.2 million will carryforward indefinitely. The Company maintains a full valuation allowance against this deferred tax asset.
At December 31, 2025, federal income tax credit carryforwards amounted to approximately $3.4 million and will expire in 2045. State income tax credit carryforwards amounted to approximately $1.4 million and begin to expire at various dates from 2025 to 2044. Additionally, the Company has approximately $0.2 million of foreign tax credits that it can carry forward through 2027. The Company maintains a full valuation allowance against these credits.
The Company has analyzed its filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as all open tax years in these jurisdictions. Should the Company need to accrue a liability for uncertain tax
benefits, any interest and penalties associated with that liability would be recorded as income tax expense. A reconciliation of the total amounts of unrecognized tax benefits, excluding interest and penalties, is as follows:
| | | | | | | | | | | | | | | | | |
| (in thousands) | 2025 | | 2024 | | 2023 |
| Balance at Beginning of the Year | $ | — | | | $ | 100 | | | $ | 443 | |
| Decreases as a Result of Tax Positions Taken in Prior Years | — | | | (100) | | | (343) | |
| | | | | |
| Balance at End of the Year | $ | — | | | $ | — | | | $ | 100 | |
There are no material penalties or interest liabilities accrued as of December 31, 2025, 2024, or 2023, nor are any material penalties or interest costs included in expense for each of the years ended December 31, 2025, 2024 and 2023. The years under which we conducted our evaluation coincided with the tax years currently still subject to examination by major federal and state tax jurisdictions, those being 2019, 2020, and 2022 through 2024 for federal purposes and 2021 through 2024 for state purposes.
Pretax income from the Company’s foreign subsidiaries amounted to approximately $9.0 million, $9.6 million and $6.5 million for 2025, 2024 and 2023, respectively. The balance of pretax earnings or loss for each of those years were domestic.
Historically, we have asserted that the unremitted earnings of our foreign subsidiaries were indefinitely reinvested. However, for the years ended December 31, 2025, 2024 and 2023, we determined that we could no longer assert indefinite reinvestment on approximately $7.0 million, $3.0 million and $1.9 million of the unremitted earnings of Luminescent Systems Canada Inc., respectively. As a result, we have recorded a deferred tax liability of approximately $0.3 million, $0.2 million, and $0.1 million at December 31, 2025, 2024 and 2023, respectively, related to local country withholding taxes that are expected to be incurred upon ultimate repatriation of such earnings. All other foreign unremitted earnings, which total approximately $17.3 million, continue to be indefinitely reinvested. We continue to be permanently reinvested in outside basis differences other than unremitted earnings as we have no plans to liquidate or sell any foreign subsidiaries. In addition, we have not provided deferred taxes on any outside basis differences of our domestic subsidiaries as we have the ability and intent to recover these basis differences in a tax-free manner. It is not practicable to determine the amount of unrecognized deferred tax related to these basis differences.
The Inflation Reduction Act of 2022 (IRA) was signed into law on August 16, 2022. Key provisions under the IRA include a 15% corporate alternative minimum tax imposed on certain large corporations and the extension and expansion of clean energy tax incentives. There were no impacts related to the IRA recorded for the years ending December 31, 2025, 2024, and 2023.
Under an Organization for Economic Co-operation and Development Inclusive Framework, countries that agreed to enact a two-pillar solution aim to address the challenges arising from the digitalization of the world economy (“Pillar Two”). Pillar Two sets out global minimum Effective Tax Rate (“ETR”) rules to ensure that large multinational businesses with consolidated revenue over €750 million are subject to a minimum ETR of 15% on income arising in low-tax jurisdictions. Rules under Pillar Two generally became effective beginning January 1, 2024 in most jurisdictions that have issued legislation. The Company will continue to monitor the impact of Pillar Two; however, Pillar Two is currently not applicable as the Company does not meet the threshold of having consolidated revenue over €750 million in two out of the four preceding years.
NOTE 12 — PROFIT SHARING/401K PLAN
The Company offers eligible domestic full-time employees participation in a safe harbor 401K plan. The plan provides for an annual company contribution. In addition, employees may contribute a portion of their salary to the plan. The plan may be amended or terminated at any time.
Total charges to income before income taxes for this plan was approximately $9.6 million, $8.9 million and $5.3 million in 2025, 2024 and 2023, respectively. The Company had funded the contributions in 2023 and the first quarter of 2024 with treasury stock in lieu of cash and funded the remainder of the 2024 contribution and the 2025 contributions with cash.
NOTE 13 — RETIREMENT PLANS AND RELATED POST RETIREMENT BENEFITS
The Company has two non-qualified supplemental retirement defined benefit plans (“SERP” and “SERP II”) for certain current and retired executive officers. The accumulated benefit obligation of the plans as of December 31, 2025 and 2024 amounts to $24.5 million and $21.4 million, respectively.
The plans provide for benefits based upon average annual compensation and years of service and, in the case of SERP, there are offsets for social security and profit sharing benefits. It is the Company’s intent to fund the plans as plan benefits become payable, since no assets exist at December 31, 2025 or 2024 for either of the plans.
The Company accounts for the funded status (i.e., the difference between the fair value of plan assets and the projected benefit obligations) of its pension plans in accordance with the recognition and disclosure provisions of ASC Topic 715, Compensation, Retirement Benefits, which requires the Company to recognize the funded status in its balance sheet, with a corresponding adjustment to Accumulated Other Comprehensive Income (“AOCI”), net of tax. These amounts will be subsequently recognized as net periodic pension cost pursuant to the Company’s historical policy for amortizing such amounts. Further, actuarial gains and losses that arise in subsequent periods and are not recognized as net periodic pension cost in the same periods will be recognized as a component of AOCI. If actuarial gains and losses exceed ten percent of the projected benefit obligation, we amortize them over the average expected future service of active participants.
Unrecognized prior service gains of $0.1 million and unrecognized actuarial gains of $0.9 million are included in AOCI at December 31, 2025 and have not yet been recognized in net periodic pension cost.
The reconciliation of the beginning and ending balances of the projected benefit obligation of the plans for the years ended December 31 is as follows:
| | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Funded Status | | | |
| Projected Benefit Obligation | | | |
| Beginning of the Year — January 1 | $ | 24,311 | | | $ | 28,798 | |
| Service Cost | — | | | — | |
| Interest Cost | 1,306 | | | 1,371 | |
| Actuarial Loss (Gain) | 2,587 | | | (6,134) | |
| Special Termination Benefits | — | | | 624 | |
| Benefits Paid | (650) | | | (348) | |
| End of the Year — December 31 | $ | 27,554 | | | $ | 24,311 | |
In 2025, the net actuarial loss of $2.6 million is due to the decrease of 11 basis points in the discount rate and change in the bonus scale used to measure the benefit obligation as of December 31, 2025 compared to the prior year. The Company incurred charges of $0.6 million in 2024 associated with a waiver of an early retirement penalty provided by the plan related to a retiring participant.
The assumptions used to calculate the projected benefit obligation as of December 31 are as follows:
| | | | | | | | | | | |
| 2025 | | 2024 |
| Discount Rate | 5.37% | | 5.48% |
| Future Average Compensation Increases | 3.50% | | 3.00% |
The plans are unfunded at December 31, 2025 and are recognized in the accompanying Consolidated Balance Sheets as a current accrued pension liability of $1.1 million and a long-term accrued pension liability of $26.5 million.
The service cost component of net periodic benefit cost is included in SG&A expenses, and all other net periodic benefit costs components (such as interest cost, prior service cost amortization and actuarial gain/loss amortization) are reported outside of operating income, within Other (Income) Expense, Net in the accompanying Consolidated Statements of Operations.
The following table summarizes the components of the net periodic cost for the years ended December 31: | | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Net Periodic Cost | | | | | |
| Service Cost — Benefits Earned During Period | $ | — | | | $ | — | | | $ | 105 | |
| Interest Cost | 1,306 | | | 1,371 | | | 1,302 | |
| Amortization of Prior Service Cost | 386 | | | 386 | | | 386 | |
| Amortization of (Gains) Losses | (1,329) | | | 738 | | | 358 | |
| Net Periodic Cost | $ | 363 | | | $ | 2,495 | | | $ | 2,151 | |
The assumptions used to determine the net periodic cost are as follows: | | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Discount Rate | 5.48% | | 4.79% | | 5.00% |
| Future Average Compensation Increases | 3.00% | | 3.00% | | 2.00% - 3.00% |
Benefit payments expected in each of the next five years are as follows: 2026 - $1.1 million, 2027 - $1.0 million, 2028 - $2.2 million, 2029 - $2.2 million, and 2030 - $2.2 million. Benefits expected to be paid in the aggregate between 2031 and 2035 are $10.3 million.
The Company is a participating employer in a trustee-managed multiemployer defined benefit pension plan for employees who participate in collective bargaining agreements. The plan generally provides retirement benefits to employees based on years of service to the Company. Contributions are based on the hours worked and are expensed on a current basis. The plan is 95.5% funded as of January 1, 2025. The Company’s contributions to the plan were $0.8 million in 2025, $0.9 million in 2024 and $0.7 million in 2023. These contributions represent less than 1% of total contributions to the plan.
NOTE 14 — SHAREHOLDERS’ EQUITY
Share Buyback Program
The Company’s Board of Directors from time to time authorizes the repurchase of common stock, which allows the Company to purchase shares of its common stock in accordance with applicable securities laws on the open market or through privately negotiated transactions. The Company has the capacity under the currently authorized program to repurchase additional shares of its common stock with a maximum dollar value of $41.5 million.
At-the-Market Equity Offering
On August 8, 2023, the Company initiated an at-the-market equity offering program (the “ATM Program”) for the sale from time to time of shares of the Company’s common stock, par value $0.01 per share having an aggregate offering price of up to $30.0 million. During the year ended December 31, 2023, the Company sold 1,334,228 shares of our Common Stock under the ATM Program. The Company generated $21.8 million in aggregate gross proceeds from sales under the ATM Program at an average sale price of $16.31 per share of Common Stock. Aggregate net proceeds from the ATM Program were $21.3 million after deducting related expenses, including commissions to the Sales Agents and issuance costs. No shares were sold under the ATM Program in 2025 or 2024. As of December 31, 2025, the Company had remaining capacity under the ATM Program to sell shares of Common Stock having an aggregate offering price up to approximately $8.2 million.
Reserved Common Stock
At December 31, 2025, approximately 7.1 million shares of Common Stock were reserved for issuance upon conversion of the Class B stock, exercise of stock options, issuance of restricted stock and purchases under the Employee Stock Purchase Plan. Class B Stock is identical to Common Stock, except Class B Stock has ten votes per share, is automatically converted to Common Stock on a one-for-one basis when sold or transferred other than via gift, devise or bequest and cannot receive dividends unless an equal or greater amount of dividends is declared on Common Stock.
Comprehensive Income (Loss) and Accumulated Other Comprehensive Loss
Comprehensive income or loss consists of net income or loss and the after-tax impact of retirement liability adjustments. No income tax effect is recorded for currency translation adjustments.
The components of accumulated other comprehensive loss are as follows:
| | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Foreign Currency Translation Adjustments | $ | (5,152) | | | $ | (8,222) | |
| Retirement Liability Adjustment – Before Tax | (1,540) | | | 2,077 | |
| Tax Benefit | 2,282 | | | 2,282 | |
| Retirement Liability Adjustment – After Tax | 742 | | | 4,359 | |
| Accumulated Other Comprehensive Loss | $ | (4,410) | | | $ | (3,863) | |
In 2025, 2024 and 2023, no tax benefit was recognized as the Company had recorded a full valuation allowance on the deferred tax asset associated with the retirement liability.
The components of other comprehensive (loss) income are as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Foreign Currency Translation Adjustments | $ | 3,070 | | | $ | (1,871) | | | $ | 984 | |
| Retirement Liability Adjustment | (3,617) | | | 7,434 | | | (884) | |
| | | | | |
| | | | | |
| Other Comprehensive (Loss) Income | $ | (547) | | | $ | 5,563 | | | $ | 100 | |
NOTE 15 — EARNINGS PER SHARE
The following table sets forth the computation of basic earnings per share:
| | | | | | | | | | | | | | | | | | | | |
| (In thousands, except per share amounts) | | 2025 | | 2024 | | 2023 |
| Basic Earnings per Common Share: | | | | | | |
| Net Income (Loss) - Basic | | $ | 29,359 | | | $ | (16,215) | | | $ | (26,421) | |
| Weighted Average Shares - Basic | | 35,443 | | | 35,037 | | | 33,104 | |
| Basic Earnings per Common Share | | $ | 0.83 | | | $ | (0.46) | | | $ | (0.80) | |
The following table sets forth the computation of diluted net income (loss) per share:
| | | | | | | | | | | | | | | | | | | | |
| (In thousands, except per share amounts) | | 2025 | | 2024 | | 2023 |
| Diluted Earnings per Common Share: | | | | | | |
| Net Income (Loss) - Basic | | $ | 29,359 | | | $ | (16,215) | | | $ | (26,421) | |
| Convertible Notes Interest Expense, Net of Tax | | — | | | — | | | — | |
| Net Income (Loss) - Diluted | | $ | 29,359 | | | $ | (16,215) | | | $ | (26,421) | |
| | | | | | |
| Weighted Average Shares - Basic | | 35,443 | | | 35,037 | | | 33,104 | |
| Net Effect of Dilutive Stock Awards | | 1,021 | | | — | | | — | |
| Net Effect of Dilutive Convertible Notes | | — | | | — | | | — | |
| Weighted Average Shares - Diluted | | 36,464 | | | 35,037 | | | 33,104 | |
| | | | | | |
| Diluted Earnings per Common Share | | $ | 0.81 | | | $ | (0.46) | | | $ | (0.80) | |
The Company includes the dilutive effect of shares issuable upon conversion of its Convertible Notes in the calculation of diluted income per share using the if-converted method. The Company has the option for the 2030 Convertible Notes to settle the conversion value in any combination of cash or shares, and as such, the maximum number of shares issuable are included in the dilutive share count if the effect would be dilutive. The Company excluded all impacts of the 2030 Convertible Notes from the computation of diluted earnings per share as the effect would be anti-dilutive. The Company will settle the principal amount of the 2031 Convertible Notes by paying cash and settle the premium in any combination of cash or shares. The Company’s average stock price during the period outstanding was below the conversion price for the 2031 Convertible Notes, therefore no incremental shares were included in diluted earnings per share.
Stock options with exercise prices greater than the average market price of the underlying common shares are excluded from the computation of diluted earnings per share because they are out-of-the-money and the effect of their inclusion would be anti-dilutive. The Company incurred a net loss for the years ended December 31, 2024 and 2023, therefore all outstanding stock options and unvested restricted stock units were excluded from the computation of diluted loss per share because the effect of their inclusion would be antidilutive.
Antidilutive shares excluded from diluted earnings (loss) per share computations were as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Stock Options and Unvested RSUs | 220 | | | 1,040 | | | 767 | |
| 2030 Convertible Notes | 5,439 | | | 553 | | | — | |
| Total Antidilutive Securities | 5,659 | | | 1,593 | | | 767 | |
The Company funded substantially all of its 2023 and a portion of its 2024 401K contributions outstanding with treasury stock in lieu of cash, and returned to cash contributions in the second quarter of 2024. The earnings per share computations for the year ended December 31, 2023 are inclusive of approximately 0.1 million in shares outstanding for the equivalent shares needed to fulfill the period’s 401K obligation using the closing share price as of December 31, 2023.
NOTE 16 — EQUITY COMPENSATION
The Company has equity compensation plans that authorize the issuance of restricted stock units or options for shares of Common Stock to directors, officers and key employees. Equity-based compensation is designed to reward long-term contributions to the Company and provide incentives for recipients to join and to remain with the Company. The exercise price of stock options, determined by a committee of the Board of Directors, is equal to the fair market value of the Common Stock on the grant date. Options become exercisable over periods not exceeding ten years and must be exercised within ten years from the grant date. The Company’s practice has been to issue new shares upon the exercise of the options.
The Company established its 2011 Incentive Stock Option Plan for the purpose of attracting and retaining executive officers and key employees, and to align management’s interest with those of the shareholders. At December 31, 2025, the Company had options outstanding for 49,887 shares under the plans.
The Company established the 2005 Directors Stock Option Plan for the purpose of attracting and retaining the services of experienced and knowledgeable outside directors, and to align their interest with those of the shareholders. At December 31, 2025, the Company had options outstanding for 23,690 shares under the plans.
During 2017, the Company established the Astronics Corporation 2017 Long Term Incentive Plan for the purpose of attracting and retaining directors, executive officers and key employees, and to align management’s interest with those of the shareholders. The Long Term Incentive Plan contemplates the use of a mix of equity award types. For stock options, the exercise price is equal to the share price on the date of grant. Upon inception, the remaining options available for future grant under the 2011 Incentive Stock Option Plan and the 2005 Directors Stock Option Plan were rolled in the Long Term Incentive Plan, and no further grants may be made out of those plans. The Long Term Incentive Plan was amended and restated in May 2021. At December 31, 2025, the Company had stock options and RSUs outstanding that covered 1,889,586 shares under the Long Term Incentive Plan, and there were 689,542 shares available for future grant under this plan.
Stock compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Vesting requirements vary for directors, officers and key employees. In general, options or RSUs granted to outside directors vest six months from the date of grant and options granted to officers and key employees straight line vest over a three- to five-year period from the date of grant. RSUs granted to officers and key employees generally cliff vest three years from the date of grant.
The following table provides compensation expense information based on the fair value of stock options and RSUs for the years ended December 31 as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Equity-based Compensation Expense | $ | 6,799 | | | $ | 8,570 | | | $ | 7,198 | |
| Tax Benefit | (1,221) | | | (1,564) | | | (1,259) | |
| Equity-based Compensation Expense, Net of Tax | $ | 5,578 | | | $ | 7,006 | | | $ | 5,939 | |
Tax benefit excludes the impact of valuation allowances recorded against deferred tax assets. In the fourth quarter of 2024, the Company entered into a Transition and Retirement Agreement with its former CFO, which granted certain benefits related to the retirement. Equity-based Compensation Expense in 2024 includes $0.6 million related with accelerated RSU vesting pursuant to that Agreement.
Stock Options | | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Weighted Average Fair Value of the Options Granted | $ | 31.97 | | | $ | 10.55 | | | $ | 8.39 | |
The weighted average fair value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions: | | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Risk-free Interest Rate | 3.72% | | 4.13% | | 4.20% - 4.33% |
| Dividend Yield | —% | | —% | | —% |
| Volatility Factor | 0.65 | | 0.61 | | 0.58 |
| Expected Life in Years | 6 years | | 7 years | | 3 - 7 years |
To determine expected volatility, the Company uses historical volatility based on weekly closing prices of its Common Stock and considers currently available information to determine if future volatility is expected to differ over the expected terms of the options granted. The risk-free rate is based on the U.S. Treasury yield curve at the time of grant for the appropriate term of the options granted. Expected dividends are based on the Company’s history and expectation of dividend payouts. The expected term of stock options is based on vesting schedules, expected exercise patterns and contractual terms.
A summary of the Company’s stock option activity and related information for the year ended December 31 is as follows: | | | | | | | | | | | | | | | | | |
| 2025 |
| (Aggregate intrinsic value in thousands) | Options | | Weighted Average Exercise Price | | Aggregate Intrinsic Value |
| Outstanding at January 1 | 1,421,493 | | | $ | 18.77 | | | $ | 50,420 | |
| Options Granted | 29,750 | | | $ | 51.72 | | | |
| Options Exercised | (111,964) | | | $ | 22.22 | | | |
| Options Forfeited / Expired | (39,575) | | | $ | 21.90 | | | |
| Outstanding at December 31 | 1,299,704 | | | $ | 19.13 | | | $ | 45,630 | |
| Exercisable at December 31 | 1,141,706 | | | $ | 18.69 | | | $ | 40,588 | |
The aggregate intrinsic value in the preceding table represents the total pretax option holder’s intrinsic value, based on the closing stock price of the Company’s Common Stock which would have been received by the option holders had all option holders exercised their options as of that date. The closing stock price of the Company’s Common Stock was $54.24, $15.96 and $17.42 as of December 31, 2025, 2024 and 2023, respectively.
Shares withheld by the Company upon the exercise of stock options to cover exercise price and satisfy tax withholding obligations represent an increase to treasury shares outstanding.
During the year ended December 31, 2025, 186,179 options vested, with a weighted average fair value of $7.52. The total fair value of options that vested during the year amounted to $1.4 million, $2.1 million and $3.0 million for the years ended December 31, 2025, 2024 and 2023, respectively. The total intrinsic value of options exercised during the year amounted to $3.6 million for the year ended December 31, 2025. No options were exercised in the years ended December 31, 2024 or December 31, 2023. During the year ended December 31, 2025, 39,575 options were forfeited with a weighted average fair
value of $10.47. At December 31, 2025, total compensation costs related to non-vested option awards not yet recognized amounts to $2.6 million and will be recognized over a weighted average period of approximately two years.
The following is a summary of weighted average exercise prices and contractual lives for outstanding and exercisable stock options as of December 31, 2025: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Outstanding | | Exercisable |
| Exercise Price Range | Shares | | Weighted Average Remaining Life in Years | | Weighted Average Exercise Price | | Shares | | Weighted Average Remaining Life in Years | | Weighted Average Exercise Price |
$9.74 – $16.55 | 879,583 | | | 6.6 | | $ | 12.46 | | | 751,336 | | | 6.4 | | $ | 11.94 | |
$22.93 – $35.61 | 390,371 | | | 2.7 | | $ | 31.68 | | | 390,370 | | | 2.7 | | $ | 31.68 | |
$45.89 – $51.72 | 29,750 | | | 9.9 | | $ | 51.72 | | | — | | | 0.0 | | $ | — | |
| 1,299,704 | | | 5.5 | | $ | 19.13 | | | 1,141,706 | | | 5.1 | | $ | 18.69 | |
Restricted Stock Units
The fair value of each RSU granted is equal to the fair market value of the Company’s Common Stock on the date of grant. The RSUs granted to employees generally cliff vest three years from the date of grant, while RSUs granted to directors cliff vest six months from the date of grant.
A summary of the Company’s RSU activity and related information for the year ended December 31 is as follows: | | | | | | | | | | | | | | |
| | 2025 |
| | RSU Shares | | Weighted Average Grant Date Fair Value |
| Unvested at January 1 | | 694,624 | | | $ | 12.39 | |
| Granted | | 259,375 | | | $ | 19.82 | |
| Vested | | (262,965) | | | $ | 14.76 | |
| Forfeited | | (27,575) | | | $ | 14.84 | |
| Unvested at December 31 | | 663,459 | | | $ | 17.88 | |
Included in total equity-based compensation expense for the year ended December 31, 2025 was $4.4 million related to RSUs. At December 31, 2025, total compensation costs related to non-vested awards not yet recognized amounts to $4.5 million and will be recognized over a weighted average period of approximately two years.
Employee Stock Purchase Plan
In addition to the stock options and RSUs discussed above, the Company has established the Employee Stock Purchase Plan to encourage employees to invest in the Company. The plan provides employees the opportunity to invest up to the IRS annual maximum of approximately $25,000 in the Company’s common stock at a price equal to 85% of the fair market value of the Company’s common stock, determined each October 1. Employees are allowed to enroll annually. Employees indicate the aggregate value of shares they wish to obtain through the program and their intention to pay for the shares through payroll deductions over the annual cycle of October 1 through September 30. Employees can withdraw anytime during the annual cycle, and all money withheld from the employees’ pay is returned. If an employee remains enrolled in the program, enough money will have been withheld from the employees’ pay during the year to pay for all the shares that the employee opted for under the program. At December 31, 2025, employees had subscribed to purchase 90,143 shares at $38.22 per share. The weighted average fair value of the options was approximately $12.66, $5.02 and $4.94 for options granted during the year ended December 31, 2025, 2024 and 2023, respectively.
The fair value for the options granted under the Employee Stock Purchase Plan was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Risk-free Interest Rate | 3.62 | % | | | 3.96 | % | | | 5.49 | % | |
| Dividend Yield | — | % | | | — | % | | | — | % | |
| Volatility Factor | 0.49 | | | 0.41 | | | 0.56 | |
| Expected Life in Years | 1.0 | | | 1.0 | | | 1.0 | |
NOTE 17 — FAIR VALUE
On a Recurring Basis:
A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There were no financial assets or liabilities carried at fair value measured on a recurring basis at December 31, 2025 or 2024.
On a Non-recurring Basis:
Long-lived assets are evaluated for recoverability whenever adverse effects or changes in circumstances indicate that the carrying value may not be recoverable. The recoverability test consists of comparing the undiscounted projected cash flows of the asset or asset group (which are Level 3 inputs) with the asset of asset group’s carrying amount. Should the carrying amount exceed undiscounted projected cash flows, an impairment loss would be recognized to the extent the carrying amount exceeds fair value. There were no impairment charges related to long-lived assets in 2025, 2024 or 2023 and no long-lived assets are required to be measured at fair value for purposes of the long-lived asset recoverability test.
Due to their short-term nature, the carrying value of cash and equivalents, restricted cash, accounts receivable and accounts payable approximate fair value. The carrying value of the Company’s variable rate long-term debt instruments also approximates fair value due to the variable rate feature of these instruments. Refer to Note 8, Long-Term Debt, for additional information relating to the fair value of the Company's outstanding fixed-rate Convertible Notes.
NOTE 18 — SELECTED QUARTERLY FINANCIAL INFORMATION
The following table summarizes selected quarterly financial information for 2025 and 2024: | | | | | | | | | | | |
| | Quarter Ended |
| (Unaudited) | December 31, | | December 31, |
| (In thousands, except for per share data) | 2025 | | 2024 |
| Sales | $ | 240,067 | | | $ | 208,540 | |
| Gross Profit (Sales Less Cost of Products Sold) | $ | 79,971 | | | $ | 62,122 | |
| | | |
| | | |
| Income Before Income Taxes | $ | 32,244 | | | $ | 576 | |
| Net Income (Loss) | $ | 29,615 | | | $ | (2,832) | |
| Basic Earnings (Loss) Per Share | $ | 0.83 | | | $ | (0.08) | |
| Diluted Earnings (Loss) Per Share | $ | 0.78 | | | $ | (0.08) | |
R&D Expenses have been reclassified from Cost of Products Sold to a separate line item below Gross Profit. All periods presented have been revised to reflect this presentation.
Income before taxes in 2025 includes a decrease in litigation-related legal expenses and legal reserve adjustments of $9.0 million compared to the prior-year period. Income before taxes in 2024 includes a loss on settlement of debt of $3.2 million.
NOTE 19 — LEGAL PROCEEDINGS AND OTHER MATTERS
Legal Proceedings
Lufthansa
On December 29, 2010, Lufthansa Technik AG (“Lufthansa”) filed a Statement of Claim in the Regional State Court of Mannheim, Germany. Lufthansa’s claim asserted that a subsidiary of the Company, AES, sold, marketed, and brought into use in Germany a power supply system that infringes upon a German patent held by Lufthansa.
In February 2015, the Regional State Court of Mannheim, Germany held that the patent was infringed.
The Company appealed to the Higher Regional Court of Karlsruhe. In November 2016, the Higher Regional Court of Karlsruhe upheld the lower court’s decision. The Company sought permission to appeal to the German Federal Supreme Court. In March 2019, the German Federal Supreme Court dismissed AES's appeal. With this decision, these proceedings are complete.
AES modified the outlet units at the end of 2014 and the overwhelming majority of the modified outlet units sold from 2015 on do not infringe the patent of Lufthansa.
In July 2017, Lufthansa filed an action in the Regional State Court of Mannheim for payment of damages caused by AES’s direct sales of the infringing power supply system into Germany (referred to as “direct sales”). A first instance decision in this matter was handed down on December 6, 2019. According to this ruling, Lufthansa was awarded damages in the amount of approximately $3.2 million plus interest. In 2020, AES made payment of $4.7 million, inclusive of interest, in satisfaction of the first instance judgment. In July 2023, the Higher Regional Court of Karlsruhe in Germany reduced the Company’s liability for direct damages on appeal from approximately $3.2 million plus interest to approximately $2.8 million plus interest. Additionally, in its judgment, the Court reduced the interest rate on damages from 5% (as held by the Regional Court of Mannheim) to 4%. Accordingly, the Company reclaimed overpaid damages and interest from LHT in the amount of approximately $1.2 million. This was recorded as an offset to Selling, General and Administrative expenses in the year ended December 31, 2023, upon receipt of the refund.
Both Lufthansa and AES have filed requests with the German Federal Supreme Court to be granted leave to file appeals against this decision.
On December 29, 2017, Lufthansa filed another infringement action against AES in the Regional State Court of Mannheim claiming that sales by AES to its international customers have infringed Lufthansa's patent if AES's customers later shipped the products to Germany (referred to as “indirect sales”). This action, therefore, addresses sales other than the direct sales covered by the action discussed above.
A first instance decision in this matter was issued in December 2019. While the Court found in favor of Lufthansa, they rejected Lufthansa's claim that AES is also liable for damages for the sale of modified products. Thus, AES is not liable for damages based on the sale of modified outlet units that removed the infringing feature. AES and Lufthansa both appealed this decision. In July 2023, the Higher Regional Court of Karlsruhe essentially upheld the first instance ruling.
According to the Higher Regional Court of Karlsruhe ruling, AES is responsible for payment of damages for indirect sales of patent-infringing in-seat power supply systems in the period from December 29, 2007 to May 22, 2018. However, because the outlet units were modified at the end of 2014, the period for which AES is liable for damages in connection with indirect sales into Germany substantially finished at the end of 2014.
Both Lufthansa and AES have filed requests with the German Federal Supreme Court to be granted leave to file appeals against this decision.
Lufthansa is expected to enforce its claim for damages in separate court proceedings. These proceedings would most likely be tried before the Mannheim Court again, which makes it probable that the Mannheim Court will determine the damages for the indirect sales based on the same principles as in the direct sales proceedings (unless the latter ruling of the Mannheim Court is reversed on appeal). Based on the information available and the determination of the damages in the direct sales claim discussed above, we estimated that the Company’s total exposure related to these matters that was probable and that could be reasonably estimated at December 31, 2025 and 2024, was approximately $11.6 million plus accrued interest. Accrued interest on the indirect damages reserve was estimated using the same interest rate as the direct damages, as were reduced on the direct damages appeal discussed above. Approximately $0.5 million, $0.7 million, and $0.7 million was recorded within Selling, General and Administrative Expenses in the Company’s Consolidated Statements of Operations for each of 2025, 2024 and 2023, respectively, for additional interest accrued during such periods.
We believe it is unlikely that the appeals process will be completed and any indirect damages and related interest will be paid before December 31, 2026. Therefore, the liability related to this matter (inclusive of accrued interest), totaling $17.6 million and $17.1 million, is classified within other liabilities (non-current) in the Consolidated Balance Sheets at December 31, 2025 and 2024, respectively. This amount may be adjusted depending on the decision of the Court on the direct sales damages appeal referred to previously.
In December 2017, Lufthansa filed patent infringement cases in the United Kingdom (“UK”) and in France. The subject patent expired in May 2018. In the normal course of its supply arrangements, AES has indemnified its customers from liability arising from such matters, and as such will bear responsibility for any monetary damages arising from such claims.
On December 4, 2020, the Court held the French patent invalid for all asserted claims, and consequently there could be no finding of infringement. Lufthansa appealed this judgment. On February 24, 2023, the Court upheld the first instance judgment in favor of AES. Lufthansa lodged an appeal before the French Supreme Court. A decision from this Court was rendered on March 19, 2025, remanding the case to the Court of Appeal of Paris for reconsideration of the invalidity of the French patent. A second trial on nullity is scheduled on October 28, 2026; a ruling on nullity is not expected before early first quarter 2027. As loss exposure is not probable and estimable at this time, the Company has not recorded any liability with respect to the French matter as of December 31, 2025 or 2024.
In the UK matter, the Court held the UK patent valid and 3 out of 4 asserted claims infringed in June 2020. In contrast to the decisions in Germany, the UK Court found that the modified components infringed a valid claim of the patent, and accordingly, the period for which AES or its customers would be liable in connection with direct sales into the UK extends until the expiration of the patent in May 2018. While AES appealed the ruling, the Court dismissed the appeal on all grounds. Lufthansa sought damages based on account of the profits that AES and certain of its customers had made from UK sales. The trial of that issue took place in October 2024. Both the Company and Lufthansa submitted to the UK High Court of Justice calculations of the estimated profits derived from the reports of the parties’ respective financial experts.
The February 21, 2025 judgment quantified the amount payable in aggregate in respect of the profits derived from infringing Lufthansa’s UK patent by the defendants as $11.9 million. Accordingly, the Company recorded additional expense of $4.8 million in the quarter ended December 31, 2024, within Selling, General and Administrative Expenses in the Company’s Consolidated Statements of Operations. The $11.9 million liability related to this matter was classified within Accrued Expenses and Other Current Liabilities in the accompanying Consolidated Balance Sheets as of December 31, 2024. Following a consequential hearing on March 20, 2025, the amount was adjusted upwards by $0.5 million related to the resolution of a provisional item.
In a further consequential hearing on May 16, 2025 the Company was ordered to make payments of $5.7 million in relation to interest and $3.5 million for partial reimbursement of Lufthansa’s legal costs. Both of these items are reflected within Selling, General and Administrative Expenses in the Company’s Consolidated Statement of Operations for the year ended December 31, 2025.
During the year ended December 31, 2025, the Company made payments totaling $21.6 million, in satisfaction of the liabilities for damages, interest and provisional legal fee reimbursement related to the damages proceedings.
Both the Company and Lufthansa have been granted permission to appeal the rulings by the UK High Court of Justice. The appeals are scheduled to be heard by the UK Court of Appeal in March 2026.
A liability for partial reimbursement of Lufthansa’s legal expenses associated with the UK matter for the first instance trial and the later appeal was approximately $1.0 million as of December 31, 2025 and 2024, which is expected to be paid within the next twelve months and, as such, is classified in Accrued Expenses and Other Current Liabilities in the accompanying Consolidated Condensed Balance Sheets as of December 31, 2025 and 2024.
Each of the German, France and UK claims are separate and distinct. Validity and infringement of the Lufthansa patent in each country is a matter for the courts in each of these countries, whose laws differ from each other. In addition, the principles of calculating damages in each jurisdiction differ substantially. Therefore, the Company has assessed each matter separately and cannot apply the same calculation methodology as in the German direct and indirect matters. However, it is reasonably possible that additional damages and interest could be incurred if the appellate court in France was to rule in favor of Lufthansa, or if damages in the UK matter upon conclusion of the appeal are calculated on a different basis than the initial judgment.
There were no other significant developments in any of these matters during the year ended December 31, 2025.
Other Proceedings
On March 23, 2020, Teradyne, Inc. filed a complaint against the Company and its subsidiary, Astronics Test Systems (“ATS”) (together, “the Defendants”) in the United States District Court for the Central District of California alleging patent and copyright infringement, and certain other related claims. The Defendants moved to dismiss certain claims from the case. On November 6, 2020, the Court dismissed the Company from the case, and also dismissed a number of claims, though the patent and copyright infringement claims remained. In addition, on November 6, 2020, ATS filed a petition for inter partes review (“IPR”) with the US Patent Trial and Appeal Board (“PTAB”), seeking to invalidate the subject patent, and on July 21, 2021, the PTAB instituted IPR. The PTAB issued its decision on July 20, 2022, in which it invalidated all of Teradyne’s patent claims. Teradyne did not appeal the decision. On December 7, 2023, the District Court granted ATS’s motion for summary judgment on its affirmative defense of fair use. The Court subsequently entered final judgment in favor of ATS on December 14, 2023. Teradyne appealed to the United States Court of Appeals for the Ninth Circuit. On January 30, 2025, the Ninth Circuit affirmed the District Court’s grant of summary judgment. Teradyne has elected not to pursue an appeal. As such, the summary judgment ruling stands and final judgment in favor of ATS has been entered. This matter is concluded.
Other than these proceedings, we are not party to any significant pending legal proceedings that management believes will result in a material adverse effect on our financial condition or results of operations. Accrued legal fees were $2.1 million and $6.5 million as of December 31, 2025 and 2024, respectively.
Other Matters
On January 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act (“IEEPA”) did not authorize the President to impose tariffs. The IEEPA tariff case has been remanded back to the Court of International Trade to address whether the lower court can issue a nationwide injunction against tariffs imposed under IEEPA. It is unknown at this time if or when refunds will be issued for IEEPA tariffs previously paid by the Company.
NOTE 20 — SEGMENTS
The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker (“CODM”) for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM, which is the Company’s Chief Executive Officer, allocates resources and assesses the performance of each operating segment based on historical and potential future product sales, gross margin associated with those sales, and operating income (loss) before interest, taxes, and corporate expenses. The Company has determined its reportable segments to be Aerospace and Test Systems based on the information used by the CODM.
Segment information and reconciliations to consolidated amounts for the years ended December 31 are as follows:
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| Sales: | | | | | |
| Aerospace | $ | 797,353 | | | $ | 706,746 | | | $ | 605,001 | |
| Less Inter-segment Sales | (34) | | | (62) | | | (171) | |
| Total Aerospace Sales | 797,319 | | | 706,684 | | | 604,830 | |
| | | | | |
| Test Systems | 65,243 | | | 88,874 | | | 84,376 | |
| Less Inter-segment Sales | (434) | | | (132) | | | — | |
| Test Systems | 64,809 | | | 88,742 | | | 84,376 | |
| Total Consolidated Sales | $ | 862,128 | | | $ | 795,426 | | | $ | 689,206 | |
Less1 | | | | | |
| Cost of Products Sold: | | | | | |
| Aerospace | $ | 548,879 | | | $ | 502,558 | | | $ | 451,911 | |
| 68.8 | % | | 71.1 | % | | 74.7 | % |
| Test Systems | $ | 55,091 | | | $ | 72,440 | | | $ | 62,763 | |
| 85.0 | % | | 81.6 | % | | 74.4 | % |
Other Segment Items2 | | | | | |
| Aerospace | $ | 135,236 | | | $ | 141,720 | | | $ | 128,290 | |
| Test Systems | $ | 17,563 | | | $ | 24,779 | | | $ | 30,358 | |
| | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| | | | | |
| Operating Income (Loss) and Margins: | | | | | |
| Aerospace | $ | 113,204 | | | $ | 62,406 | | | $ | 24,629 | |
| 14.2 | % | | 8.8 | % | | 4.1 | % |
| Test Systems | (7,845) | | | (8,477) | | | (8,745) | |
| (12.1) | % | | (9.6) | % | | (10.4) | % |
| Total Operating Income (Loss) | $ | 105,359 | | | $ | 53,929 | | | $ | 15,884 | |
| 12.2 | % | | 6.8 | % | | 2.3 | % |
| Additions to (Deductions from) Operating Profit: | | | | | |
| Net Gain on Sale of Businesses | $ | — | | | $ | — | | | $ | 3,427 | |
| Loss on Settlement of Debt | (32,644) | | | (10,148) | | | — | |
| Interest Expense, Net of Interest Income | (12,561) | | | (21,998) | | | (23,328) | |
| Corporate and Other Expenses, Net | (28,209) | | | (29,650) | | | (22,294) | |
| Income (Loss) before Income Taxes | $ | 31,945 | | | $ | (7,867) | | | $ | (26,311) | |
| | | | | |
1 The significant expenses and amounts presented align with the segment-level information that is regularly provided to the CODM. Inter-segment expenses are included within the amounts shown. 2 Other segment items include Selling, General and Administrative Expenses, Research and Development Expenses, and sublease and rental income. |
| | | | | |
| Depreciation and Amortization: | | | | | |
| Aerospace | $ | 18,866 | | | $ | 19,458 | | | $ | 20,801 | |
| Test Systems | 2,932 | | | 4,813 | | | 5,068 | |
| Corporate | 40 | | | 195 | | | 235 | |
| Total Depreciation and Amortization | $ | 21,838 | | | $ | 24,466 | | | $ | 26,104 | |
| | | | | |
| Assets: | | | | | |
| Aerospace | $ | 570,294 | | | $ | 498,528 | | | |
| Test Systems | 119,603 | | | 128,828 | | | |
| Corporate | 16,781 | | | 21,408 | | | |
| Total Assets | $ | 706,678 | | | $ | 648,764 | | | |
| Capital Expenditures: | | | | | |
| Aerospace | $ | 30,741 | | | $ | 7,346 | | | $ | 5,003 | |
| Test Systems | 932 | | | 1,066 | | | 2,640 | |
| Corporate | — | | | 16 | | | — | |
| Total Capital Expenditures | $ | 31,673 | | | $ | 8,428 | | | $ | 7,643 | |
During the year ended December 31, 2024 and 2023, reserves associated with customer bankruptcies of $3.2 million and $11.1 million, respectively, negatively impacted Aerospace Operating Income.
During the year ended December 31, 2023, $5.8 million was recognized in sales related to the reversal of a deferred revenue liability assumed with an acquisition and associated with a customer program within our Test Systems Segment which is no longer expected to occur, which also benefits Test Systems’ operating loss for the year.
Corporate expenses and other for the year ended December 31, 2023, includes income of $1.8 million associated with the reversal of a liability related to an equity investment, as we are no longer required to make the associated payment. This amount is included in Other Income, Net. The higher level of Aerospace capital expenditures in 2025 is related to ongoing facility expansion activities and growth and maintenance expenditures that had been previously deferred during the pandemic.
The following table summarizes the Company’s sales into the following geographic regions for the years ended December 31: | | | | | | | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 | | 2023 |
| United States | $ | 615,096 | | | $ | 593,943 | | | $ | 518,096 | |
| North America (excluding United States) | 14,635 | | | 13,107 | | | 14,878 | |
| Asia | 73,265 | | | 44,176 | | | 26,165 | |
| Europe | 153,396 | | | 139,384 | | | 123,682 | |
| South America | 2,117 | | | 1,445 | | | 2,071 | |
| Other | 3,619 | | | 3,371 | | | 4,314 | |
| Total | $ | 862,128 | | | $ | 795,426 | | | $ | 689,206 | |
The following table summarizes the Company’s property, plant and equipment by country for the years ended December 31: | | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| United States | $ | 97,325 | | | $ | 73,749 | |
| France | 6,507 | | | 5,625 | |
| Germany | 2,155 | | | — | |
| India | 255 | | | 357 | |
| Canada | 836 | | | 956 | |
| Total | $ | 107,078 | | | $ | 80,687 | |
Sales recorded by the Company’s foreign operations were $90.1 million, $82.1 million and $69.3 million in 2025, 2024 and 2023, respectively. Net income from foreign operations was $8.2 million, $7.6 million and $5.3 million in 2025, 2024 and 2023, respectively. Net assets held outside of the U.S. total $67.8 million and $41.3 million at December 31, 2025 and 2024, respectively. The exchange gain (loss) included in determining net income was insignificant in 2025, 2024 and 2023. Cumulative translation adjustments amounted to $5.2 million and $8.2 million at December 31, 2025 and 2024, respectively.
The Company has a significant concentration of business with The Boeing Company (“Boeing”). Sales to Boeing are primarily in the Aerospace segment. The following is information relating to the activity with this customer:
| | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Percent of Consolidated Sales | | | | | |
| Boeing | 10.4% | | 10.2% | | 11.0% |
| | | | | | | | | | | |
| (In thousands) | 2025 | | 2024 |
| Accounts Receivable at December 31, | | | |
| Boeing | $ | 19,679 | | | $ | 10,474 | |
NOTE 21 — ACQUISITIONS
Envoy Aerospace, LLC
On June 30, 2025, the Company purchased the membership interests of Envoy Aerospace, LLC (“Envoy Aerospace”), located in Aurora, Illinois. Envoy Aerospace is an FAA Organization Designation Authorization (“ODA”) services provider. Envoy Aerospace is included in our Aerospace segment. The total purchase price was approximately $8.3 million, net of cash acquired and the estimated closing adjustment. Of the purchase price, $4.5 million was paid at the closing date. Payments of $2.0 million and $1.8 million will become payable by the Company following the first and second anniversary of the closing date, respectively, based on the achievement of certain milestones. The Company has finalized the purchase price allocation. Purchased intangible assets and goodwill are expected to be deductible for tax purposes over 15 years. This transaction was not considered material to the Company’s financial position or results of operations.
Bühler Motor Aviation
On October 13, 2025, the Company acquired all of the issued and outstanding capital stock of Bühler Motor Aviation (“BMA”), located in Uhldingen-Mühlhofen, Germany. BMA is an established manufacturer of aircraft seat actuation systems with a broad product portfolio that includes actuators, electronics, control panels, pneumatic systems, and lighting. BMA will be included in our Aerospace segment. The total purchase price was approximately $18.0 million, net of cash acquired and the estimated
closing adjustment. The purchase price was paid at the closing date. The Company has not yet finalized the purchase price allocation.
NOTE 22 — DIVESTITURE ACTIVITIES
Semiconductor Test Business
On February 13, 2019, the Company completed a divestiture of its semiconductor test business within the Test Systems segment. The total proceeds of the divestiture included contingent purchase consideration (“earnout”). In March 2023, the Company agreed with a final earnout calculation in the amount of $3.4 million. The Company recorded the gain and received the payment in the first quarter of 2023. We are not eligible for any further earnout payments related to this divestiture.